ASCO Annual Meeting | Conference

Long-Term Data Deepen Dabrafenib/Trametinib Benefit in Melanoma

June 7th 2016

The combination of dabrafenib and trametinib continued to demonstrate impressive overall survival and progression-free survival findings for patients with BRAF-mutant metastatic melanoma in 3-year follow-up data from the phase III COMBI-d study.

Dr. Dummer on NEMO Trial for NRAS-Mutant Melanoma

June 7th 2016

Reinhard Dummer, MD, professor, Department of Dermatology, University of Zurich Hospital, discusses the results of the phase III NEMO trial, which compared the efficacy of binimetinib with dacarbazine in patients with NRAS-mutant metastatic melanoma.

Alectinib Could Represent First-Line Standard in ALK-Positive NSCLC

June 7th 2016

Alectinib improved progression-free survival by 66% compared with the current standard crizotinib as initial inhibitor therapy in patients with advanced or recurrent ALK-positive non–small cell lung cancer.

Long-Term Follow-up Sustains Frontline Nivolumab/Ipilimumab Benefit in Melanoma

June 7th 2016

At a minimum follow-up of 18 months, the combination of nivolumab and ipilimumab reduced the risk of disease progression by 58% compared with ipilimumab alone, and single-agent nivolumab lowered the risk of progression by 45% versus ipilimumab monotherapy in patients with advanced melanoma.

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

June 7th 2016

David A. Reardon, MD, discusses results of a cohort from the open-label CheckMate-143 trial, which explored the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with recurrent glioblastoma multiforme (GBM).

Binimetinib Shows Rare PFS Benefit in NRAS-Mutant Melanoma

June 7th 2016

The MEK inhibitor binimetinib reduced the risk of progression or death by 38% compared with dacarbazine in patients with NRAS-mutant metastatic melanoma.

PD-L1 Inhibitor Avelumab Active in Advanced Mesothelioma

June 7th 2016

Avelumab demonstrated clinical activity in patients with advanced or unresectable mesothelioma, with an overall response rate of 14.3%.

Nivolumab Improves OS, ORR in Phase III Head and Neck Cancer Study

June 7th 2016

Treatment with single-agent nivolumab improved overall survival and objective response rates compared with investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma.

Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction

June 7th 2016

Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.

Despite Recommendations, Aggressive Cancer Treatment Still Common at End of Life

June 6th 2016

An analysis of over 28,000 patients younger than 65 with incurable cancers found that approximately three-fourths of them received aggressive care within the last 30 days of life and one-third died in the hospital.

Web App Boosts Survival for Lung Cancer Patients

June 6th 2016

Patients with lung cancer who participated in a web-based system for reporting and tracking their symptoms achieved dramatic gains in survival compared with individuals who were followed with typical protocols.

Cancer Drugs Less Affordable in Poorer Countries Despite Lower Prices

June 6th 2016

Researchers who set out to understand the affordability of cancer drugs across the globe concluded that lower prices in some poorer countries don’t equate to better access.

Dabrafenib/Trametinib Combo Highly Effective in BRAF-Mutant NSCLC

June 6th 2016

The combination of dabrafenib and trametinib was highly effective as a treatment for patients with BRAF V600E-mutant non–small cell lung cancer.

Nivolumab Delivers Durable Responses in Hodgkin Lymphoma

June 6th 2016

Single-agent nivolumab induced responses in 66% of patients with classical Hodgkin lymphoma who had progressed following autologous stem cell transplant and brentuximab vedotin.

Nivolumab 5-Year OS Rate Passes 30% in Advanced RCC

June 6th 2016

About one third of patients with advanced renal cell carcinoma who were treated with single-agent nivolumab in the second-line setting or later were still alive at 4 and 5 years in long-term follow-up data from phase I and phase II clinical trials.

Atezolizumab Effective in First-Line Setting in Bladder Cancer

June 6th 2016

Patients with metastatic urothelial carcinoma who were ineligible for standard cisplatin-based chemotherapy achieved a 24% reduction in tumor size and had a median survival of 14.8 months after taking the immunotherapy agent atezolizumab (Tecentriq).

Bernard Fox on Significance of Immunoscore Validation Project

June 6th 2016

Bernard A. Fox, PhD, chief, Laboratory of Molecular and Tumor Immunology, Earle A. Chiles Research Institute at Providence Portland Medical Center, discusses the significance of the Immunoscore Validation Project.

Extending AI Therapy Beyond 5 Years Reduces Recurrence in HR-Positive Breast Cancer

June 6th 2016

Women who extended their adjuvant therapy with an aromatase inhibitor to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.

Dr. Balar on IMvigor 210 Results for Metastatic Urothelial Carcinoma

June 6th 2016

Arjun V. Balar, MD, assistant professor, Department of Medicine, co-leader of the Genitourinary Cancers Program, discusses updated results of cohort 1 of the IMvigor 210 study, which examined the efficacy of atezolizumab as first-line therapy in patients with cisplatin-ineligible locally advanced/metastatic urothelial carcinoma.

Survival in Recurrent GBM Surpasses Historical Results with Gene Therapy

June 6th 2016

A novel antiangiogenic gene therapy, added to bevacizumab, led to significantly better overall survival in recurrent glioblastoma multiforme compared with historical patients treated with bevacizumab alone, a small phase II trial showed.